Related Experiment Video
Updated: May 10, 2025

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
Published on: August 31, 2014
p17 Variant Expression and Evolution in HIV-Mediated Lymphomagenesis.
Nicoleta Arnaut1, Mark Slevin1, Claudia Bănescu1,2
1Centre for Advanced Medical and Pharmaceutical Research, "George Emil Palade" University of Medicine, Pharmacy, Science and Technology, 540142 Targu Mures, Romania.
Specific p17 variants (vp17s) with C-terminal amino acid insertions are more common in individuals with HIV-1 and lymphoma. These vp17s may serve as biomarkers for lymphoma risk in HIV-positive patients.
Area of Science:
- Oncology
- Virology
- Molecular Biology
Background:
- Non-Hodgkin lymphoma (NHL) is a leading cause of death in individuals with human immunodeficiency virus (HIV-1), persisting despite combined antiretroviral therapy (cART).
- The precise mechanisms driving B-cell tumorigenesis in HIV-1-positive individuals are not fully understood.
- Recent research highlights a significant role for p17 variants (vp17s) in the development of lymphoma.
Purpose of the Study:
- To elucidate the role of specific p17 variants (vp17s) in lymphomagenesis among HIV-1-positive individuals.
- To evaluate the potential of vp17s as diagnostic and prognostic markers for identifying patients at high risk of lymphoma.
- To explore the molecular mechanisms by which vp17s contribute to lymphoma development.
Main Methods:
- Comparative analysis of vp17 sequences in HIV-1-positive individuals with and without lymphoma.
- Utilizing ultradeep sequencing technologies, such as next-generation sequencing, for comprehensive vp17 analysis.
- Investigating the interaction of altered vp17s with protease-activated receptor-1 (PAR-1) and downstream signaling pathways like protein kinase B.
Main Results:
- vp17s with specific C-terminal amino acid insertions (at positions 114-115, 117-118, and 125-126) were significantly more prevalent in HIV-1-positive patients with lymphoma compared to those without.
- These alterations destabilize the vp17 protein, exposing a functional epitope that interacts with PAR-1.
- This interaction stimulates the protein kinase B pathway, suggesting an oncogenic role for these vp17 variants.
Conclusions:
- Specific vp17 variants with C-terminal amino acid insertions are strongly associated with lymphoma development in HIV-1-positive individuals.
- These lymphomagenic vp17s represent potential biomarkers for early detection and risk stratification of lymphoma in this population.
- Next-generation sequencing can be a valuable tool for screening and monitoring HIV-1-positive patients, enabling targeted preventive strategies against lymphoma.
Related Concept Videos
Non-LTR Retrotransposons
Viral Mutations
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Epistasis
LTR Retrotransposons
The internal coding region of LTR retrotransposons and their mechanism of transposition closely resembles a...

